Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yanshao Lidan is a Traditional Chinese Medicine (TCM) preparation developed by Hunan Zhongjia Pharmaceutical Development Co., Ltd., specifically indicated for the treatment of chronic calculous cholecystitis. The formulation is a combination of several herbal ingredients, most notably *Bergenia purpurascens* (Yanbaicai) and *Paeonia lactiflora* (Baishao), which are traditionally recognized for their ability to clear heat, promote diuresis, and benefit the gallbladder. Mechanistically, the drug functions as a choleretic to increase bile secretion and flow, while also providing anti-inflammatory and analgesic effects to reduce gallbladder wall thickening and alleviate abdominal pain. It is typically administered orally in tablet form to manage symptoms associated with gallstones and chronic gallbladder inflammation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Yanshao Lidan.